Ergamisol

(Levamisole)

ApprovedSmall molecule

WWim Janssens

Ergamisol is one of 108 small molecule programs targeting Hemolytic Anemia. It is currently in Approved.

Indications

Total Trials

Active Trials

107

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Hemolytic AnemiaActive, not recruiting

Nephrotic SyndromeActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

COVID-19Active, not recruiting

Hemolytic AnemiaPhase 2

Active, not recruiting

Nephrotic SyndromeApproved

Active, not recruiting

Hepatocellular CarcinomaPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Ergamisol

WWim Janssens

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

COVID-19 Vaccine

Moderna

Preclinical

27 4

Biaxin

AbbVie

Preclinical

2 5

Aldactone

Pfizer

Preclinical

1 6

Nexavar

Bayer

Preclinical

1 7

Activella

Eli Lilly

Preclinical

—8

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 9

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Azithromycin1 trial

Comparison of Efficacy of Azithromycin and Levamisole Versus of Azithromycin in in the Treatment of Acne

Completed·—·Phase 2/3·NCT01348321·169 enrolled

Nephrotic Syndrome1 trial

The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children

Recruiting·JJianhua Zhou·Phase 4·NCT05772871·402 enrolled

Dialysis Patients1 trial

Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients

Completed·SShiraz University of Medical Sciences·Phase 2·NCT00705692·40 enrolled

Hepatocellular Carcinoma1 trial

Novel Treatment of Advanced Hepatocellular Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 3·NCT03950518·300 enrolled

Efficacy1 trial

Efficacy Albendazole and Levamisole Against STH on Unguja

Completed·NNatural History Museum, United Kingdom·Phase 4·NCT00659997·20 enrolled

2 more indications

COVID-191 trial

Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19

Unknown status·—·Phase 3·NCT04360122·100 enrolled

Hemolytic Anemia1 trial

Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT01579110·100 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 18, 1990

ERGAMISOL

NDA NDA020035

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Levamisole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levamisole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levamisole. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020035). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wim Janssens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWim Janssens

Ergamisol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Azithromycin1 trial

Nephrotic Syndrome1 trial

Dialysis Patients1 trial

Hepatocellular Carcinoma1 trial

Efficacy1 trial

COVID-191 trial

Hemolytic Anemia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News